We have located links that may give you full text access.
Clinical Trial, Phase I
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Treatment Zone Decentration During Orthokeratology on Eyes with Corneal Toricity.
Optometry and Vision Science : Official Publication of the American Academy of Optometry 2016 September
PURPOSE: To compare the magnitude of treatment zone decentration between eyes with minimally toric corneas (≤1.50 DC, LoTor group) and eyes with moderately toric corneas (1.50 to 3.50 DC, HiTor group) after a single overnight wear of spherical orthokeratology lenses.
METHODS: In the LoTor group, 21 participants (9 M, 12 F, 20-40 years) were fitted using a conventional fitting approach based on the flat corneal meridian. In the HiTor group, 12 participants (5 M, 7 F, 19-45 years) were fitted using the conventional fitting method in one eye (HiTor group I) and the other eye was fitted with a lens with slightly deeper sagittal height (HiTor group II). In all groups, BE spherical orthokeratology trial contact lenses (Boston XO) were used and corneal topography data (Medmont E300) were obtained at baseline and after a single overnight wear. The magnitude of treatment zone decentration relative to vertex normal was determined from corneal topography refractive power difference maps. Treatment zone parameters including magnitude and direction of decentration were analyzed and related to baseline corneal parameters.
RESULTS: After a single overnight wear, the mean magnitude of treatment zone decentration was 0.48 ± 0.20 mm in the LoTor group, 1.06 ± 0.57 mm in HiTor group I, and 0.95 ± 0.44 mm in HiTor group II. Treatment zone decentration in the LoTor group was significantly different from HiTor group I (p < 0.001), both fitted using a conventional fitting method. Treatment zone decentration was not significantly different between HiTor group I and II (p = 0.606). The magnitude of treatment zone decentration was positively correlated with the amount of baseline corneal toricity (LoTor and HiTor group I combined, p = 0.048).
CONCLUSIONS: Eyes with higher amounts of corneal toricity give rise to increased amounts of treatment zone decentration in overnight orthokeratology.
METHODS: In the LoTor group, 21 participants (9 M, 12 F, 20-40 years) were fitted using a conventional fitting approach based on the flat corneal meridian. In the HiTor group, 12 participants (5 M, 7 F, 19-45 years) were fitted using the conventional fitting method in one eye (HiTor group I) and the other eye was fitted with a lens with slightly deeper sagittal height (HiTor group II). In all groups, BE spherical orthokeratology trial contact lenses (Boston XO) were used and corneal topography data (Medmont E300) were obtained at baseline and after a single overnight wear. The magnitude of treatment zone decentration relative to vertex normal was determined from corneal topography refractive power difference maps. Treatment zone parameters including magnitude and direction of decentration were analyzed and related to baseline corneal parameters.
RESULTS: After a single overnight wear, the mean magnitude of treatment zone decentration was 0.48 ± 0.20 mm in the LoTor group, 1.06 ± 0.57 mm in HiTor group I, and 0.95 ± 0.44 mm in HiTor group II. Treatment zone decentration in the LoTor group was significantly different from HiTor group I (p < 0.001), both fitted using a conventional fitting method. Treatment zone decentration was not significantly different between HiTor group I and II (p = 0.606). The magnitude of treatment zone decentration was positively correlated with the amount of baseline corneal toricity (LoTor and HiTor group I combined, p = 0.048).
CONCLUSIONS: Eyes with higher amounts of corneal toricity give rise to increased amounts of treatment zone decentration in overnight orthokeratology.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app